Navigation Links
Vasogen to Conduct Year-end 2007 Conference Call
Date:1/11/2008

tal on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a
'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
2. Vasogen Provides an Update on ACCLAIM-II Preparations
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Announces Third Quarter 2007 Results
5. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
6. Hybrid semiconductors show zero thermal expansion; Could lead to hardier electronics
7. Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease
8. NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
9. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
10. Doping technique brings nanomechanical devices into the semiconductor world
11. IBM and Imago find a crucial difficulty in semiconductor device scaling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Massachusetts , September 19, 2014 ... the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... of science and medical research in the field of ... Merck KGaA, Darmstadt, Germany , today ... Innovation (GGI) for 2014. The awards were announced during ...
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... , Sept. 18, 2014 ... of the "Global N-acetylcysteine Industry Report 2014" ... The Global N-acetylcysteine Industry Report 2014 is a ... of the global N-acetylcysteine industry. The ... including definitions, classifications, applications and industry chain structure. ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2
... TORONTO, April 3, 2012  Generex Biotechnology Corporation (OTCBB: GNBT.OB) ... (AACR) chose to spotlight a presentation on data from ... to prevent relapse in patients who have had breast ... conference.  The annual AACR meeting is one of the ...
... CAMBRIDGE, Mass., April 2, 2012   Good Start Genetics ,™ ... standard in carrier screening , today announced it completed ... Stock financing, which was led by existing investors OrbiMed ... SFE ) and SV Life Sciences . Proceeds from ...
... important step forward in developing a new material using nano-sized ... devices, with greater capacity than is currently feasible, in a ... Many modern data storage devices, like hard disk ... tiny individual magnetic sections, but their overall design is limited ...
Cached Biology Technology:Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 2Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 3Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 4Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 2Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 3Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 4Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 5Honeycombs of magnets could lead to new type of computer processing 2Honeycombs of magnets could lead to new type of computer processing 3
(Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
(Date:9/18/2014)... N.Y. A sleep-promoting circuit located deep in the ... sleep. Discovered by researchers at Harvard School of Medicine ... Biomedical Sciences, this is only the second "sleep node" ... be both necessary and sufficient to produce deep sleep. ... , the study demonstrates that fully half of all ...
(Date:9/18/2014)... "frequent flyers" program, fruit flies surely would be eligible ... increasing numbers of fruit fly research studies. One fruit ... and another is scheduled launch to the station Sept. ... December. , Fruit flies are biomedical research models studied ... organisms can reveal the basis for health and disease ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... 11 genotypes that may increase esophageal cancer risk, according ... Cancer Prevention Research, a journal of the American ... increased risk of esophageal cancer with increasing numbers of ... the Department of Epidemiology at the University of Texas ...
... in Genome Research on Nov. 4, scientists at ... previously believed to be "junk" DNA is one of the ... 50 percent of human DNA has been referred to as ... A major source of these repeats is internal viruses that ...
... online, open-access journal PLoS ONE , led by ... children who study a musical instrument for at least ... in tests of auditory discrimination and finger dexterity (skills ... also on tests measuring verbal ability and visual pattern ...
Cached Biology News:Genetic predictors of esophageal cancer identified 2'Junk' DNA proves functional 2'Junk' DNA proves functional 3Research shows that time invested in practicing pays off for young musicians 2
... Vector NTI allows you to store and ... data in a secure central relational database. ... creates an invaluable resource for clone tracking ... easily for immediate analysis. LabShare software integrates ...
... Protein A and Protein G bind ... immunoglobulins. Protein A and Protein G conjugates ... purify immunoglobulins (antibodies) and immunoglobulin subtypes from ... and other biological fluids. These reagents are ...
... Description: ,Kit containing Dermal Fibroblasts (Mouse/BalbC) ... as a long-term culture, and is guaranteed ... continuous growth from the date supplied, when ... Dermis, mouse/BalbC, embryonic day 18.5 ,Applications: ...
... Protein A and Protein G bind specifically ... Protein A and Protein G conjugates are ... immunoglobulins (antibodies) and immunoglobulin subtypes from serum, ... other biological fluids. These reagents are also ...
Biology Products: